Earnings release
Page 1
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . 2 Henlius Shanghai Henlius Biotech , Inc. 上海 復 宏 漢 霖 生物 技術 股份有限公司 ( A joint stock company incorporated in the People's Republic of China with limited liability ) ( Stock Code : 2696 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021 The board of directors ( the “ Board ” ) of Shanghai Henlius Biotech , Inc. ( the “ Company ” or “ Henlius ” ) is pleased to announce the unaudited consolidated financial results of the Company and its subsidiaries ( collectively referred to as the “ Group ” or “ we ” ) for the six months ended 30 June 2021 ( the “ Reporting Period ” ) , prepared under International Financial Reporting Standards ( " IFRSS " ) . FINANCIAL SUMMARY : 1 . 2 . 3 . The Group's total revenue increased by approximately RMB523.2 million or approximately 474 % to approximately RMB633.6 million for the six months ended 30 June 2021 , compared to approximately RMB110.4 million for the six months ended 30 June 2020. Such revenue was mainly from drug sales , research and development ( “ R & D ” ) services provided to customers , and license revenue . For the six months ended 30 June 2021 , the Group recognised R & D clinical expenditure of approximately RMB739.3 million , representing a decrease of approximately RMB17.6 million as compared with approximately RMB756.9 million for the six months ended 30 June 2020 , mainly due to strategic adjustments in projects and timing differences . The Group's total loss decreased by approximately RMB54.2 million to approximately RMB393.8 million for the six months ended 30 June 2021 , compared to approximately RMB448.0 million for the six months ended 30 June 2020 , mainly due to the successive commercialization of key products . 1